Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. Review uri icon

Overview

abstract

  • Obesity is a growing epidemic in the USA with over one third of adults presently classified as obese. Obesity-related comorbidities include many leading causes of preventable death such as heart disease, stroke, type 2 diabetes, and certain types of cancer. Modest weight loss of 5-10 % of body weight is sufficient to produce clinically relevant improvements in cardiovascular disease risk factors among patients with overweight and obesity. Until recently, there were limited pharmacologic options approved by the Food and Drug Administration to treat obesity. Phentermine/topiramate ER and lorcaserin were approved in 2012, and naltrexone SR/bupropion SR and liraglutide 3.0 mg were approved in 2014. This article reviews recent literature in the field of Obesity Medicine and highlights important findings from clinical trials. Future directions in the pharmacologic management of obesity are presented along with new diabetes medications that promote weight loss and reduce cardiovascular mortality.

publication date

  • July 1, 2016

Research

keywords

  • Anti-Obesity Agents
  • Obesity

Identity

Scopus Document Identifier

  • 84971612134

Digital Object Identifier (DOI)

  • 10.1007/s11883-016-0589-y

PubMed ID

  • 27181165

Additional Document Info

volume

  • 18

issue

  • 7